A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

NCT01035216 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped This study has been terminated.

Conditions

Leukemia

Interventions

DRUG: GNKG168

Sponsor

SBI Biotech Co., Ltd.